Member Info for RuckRover

Chester,

10 minutes later - I wouldn't want to wait that long. How about a live feed from the hospital like when Mary Keenan got the first Covid vaccination.

Seriously though, if there isn't a serious adverse reaction I'd expect an announcement after 2-3 days. If there were a serious adverse reaction I'd expect an RNS immediately.

Personally, I'm not expecting a big price movement on FPD - we know the trial has been approved, we know there are people needing treatment so it is only a matter of time - FPD is inevitable.

The RNSs on the research agreements do state clearly "non-exclusive"

Hasiba,

You can forget earnings and dividend yields for many years to come.

SCLP are valued purely on potential. There is a big risk with any bio that the potential will not be reached - this is why the SP is 16p and not £4!
The further down the trial path, the less the risk becomes. So we don't need to get market, revenue earnings and dividends before investors get a "return".
FPD, safety data, efficacy data, completion of P1 are all milestones that should enhance then SP.
I guess you know all this, hence your investment here.

Should be called britishBull***t.

The MODI1 trial has finally started since its discovery nearly 10 years ago.
It is targeting 4 hard to treat cancers that have a market worth $16B pa.
Scancell are well funded to take these trials to at least a point where value is proven.

Show me any of that in a chart.
The charts are self fulfilling and influenced by traders who do not understand the significance of the above.

Well at £12.50 per trade, I'm sure my platform would be more than happy if I bought shares one at a time!

Sorry, I hadn't noticed that link had already been posted by Marcus (thanks to TF).

It really is worth a read or re-read if you already have. Some amazing stuff to come I feel.

He also presented at the 2021 AGM....

https://www.scancell.co.uk/Data/Sites/1/media/docspres/scancell-2021-agm_all_final_corrected.pdf

So like I say, still very much involved!

Prof Ottensmeier was appointed to the clinical advisory board in May 2019....

Scancell Holdings has appointed six world-leading clinicians to establish its Clinical Advisory Board (CAB). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support. This will be especially needed as the cancer immunotherapy company prepares for its lead Moditope candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.

The CAB comprises:

Professor Robert Coleman, Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield
Professor Christian Ottensmeier, Professor of Experimental Cancer Medicine at the University of Southampton
Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust
Professor Iain McNeish, Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London Professor David Miles, Lead Clinician for breast cancer at Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital

From the RNS 26th August 2021...

Professor Lindy Durrant, Chief Executive Officer, Scancell, commented: “The approval of the Modi-1 CTA
is a significant achievement for the Company. Targeting siPTMs generated dramatic regression of large
tumours in our preclinical models and we hope to see similar results in cancer patients during this trial. This is
the first of several vaccines that we are developing from the Moditope® platform and look forward to updating
the market on our progress in due course.”
Professor Christian Ottensmeier at The Clatterbridge Cancer Centre and University of Liverpool,
commented: “I am very excited to be the principal investigator for this first-in-human clinical trial to determine
if siPTMs and, in particular, citrullination will be able to transform the prognosis for these patients with hard to
treat tumours.”
Professor Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals, commented: “We are delighted to
be collaborating with Scancell on this innovative trial. We have shown that AMPLIVANT® is an excellent
adjuvant for therapeutic vaccines and think that extending the scope of our technology to targeting siPTMs
could have enormous benefit for patients with a range of solid tumours.“
Julie Crane, Centre Manager of Liverpool Head and Neck Centre (LHNC), commented: “On behalf of
LHNC, I am delighted that this exciting novel, first-in-human treatment will be available for our head and neck
patients.”

Just to be clear, Clatterbridge Liverpool is one of the ModiFY centres and the contact is professor Ottensmier. So he is still very much involved.

Many thanks Burble.

The MODI1 trail targets four different cancer types - TNBC, Ovarian, Head and Neck and Renal.

Presumably there is only one MODI1 formulation and this will be used on all cancer types above.
So a couple of questions:

1) What do the four types have in common that makes them targets for MODI1?

2) Are we expecting if t work better against some of the targets than others?

Surely as an advisor you told her shares can go down as well as up?

Cleaner,
You are an FSA occasionally?
Who's the "he" who sold the shares - I thought you were talking about your daughter?

Hasiba,
Never mind "clear progress visibility news". If this "melts away tumours in four days" in humans as it did in mice, there won't be any resistence!

We may well have been told that. Doesn't mean it will definitely happen though does it?

It's becoming a familiar pattern

C7,
I'm not sure about packaging the whole of Immunobody with Covidity. I can see SCOV being sold off separately and SCLP concentrating on oncology. I think if they are sold off, they will be to two separate parties.
Just my opinion.

C7,
I can't say whether or not it makes sense that SAR is valued more than SCLP as I don't know enough about SAR. At a quick glance it looks like SAR's strategy is to do research and license. This may be seen as a lower risk strategy than SCLP's (which isn't that clear anyway).
Whatever we are worth right now without data and without deals (I'd say 28p-38p) isn't significant. Once we get some MODI data (assuming good) we should be in the 40p to 50p range easily.
We have got to be a £500M company surely?

Thanks crumbs/C7.

So it would appear SCIB2 is indeed on hold. A new iSCIB1 and iSCIB2 may be on the cards in the future.
When I said "no mention" of SCIB2 I was referring to the projected revenue figures making up the company valuation. Covidity was also missing from any financial projections.